Madrigal Pharmaceuticals, Inc. (Nasdaq: MGDL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need.
Location: United States, Pennsylvania, Conshohocken
Employees: 51-200
Founded date: 2011
Investors 4
| Date | Name | Website |
| 13.07.2025 | Foresite C... | foresiteca... |
| 23.03.2023 | Avoro Capi... | avorocapit... |
| 18.02.2025 | Hercules C... | htgc.com |
| - | Bay City C... | baycitycap... |
Mentions in press and media 24
| Date | Title | Description |
| 21.03.2026 | Condor Software Secures $24M to Revolutionize Life Sciences Financial Intelligence | Condor Software, a San Diego innovator, secured $24 million in Series A funding. This pivotal round, led by Insight Partners, propels the company's total capital to $36 million. Condor fundamentally transforms life sciences financial operat... |
| 19.03.2026 | Condor Software: $24 Million Raised To Build Financial Intelligence Platform For Life Sciences | Condor Software announced it has raised $24 million in a Series A funding round led by Insight Partners, with participation from Felicis, 645 Ventures, Pamir Ventures, SNR Ventures, Prebys Ventures, and Bramalea Partners. The company has no... |
| 27.02.2026 | Global Pharma Giants Bet Big on China's Weight-Loss Innovations | Pfizer significantly invests in China's surging weight-loss drug market. A landmark partnership with Sciwind Biosciences grants Pfizer exclusive commercialization rights for Ecnoglutide, a cutting-edge GLP-1 receptor agonist, in mainland Ch... |
| 25.02.2026 | Pfizer, Other Global Pharma Giants Are Pouring Big Bucks Into Licensing Chinese Weight-Loss Drugs | (Yicai) Feb. 25 -- Global pharmaceutical heavyweights, including the likes of Pfizer and AstraZeneca, are shelling out huge sums to secure the licensing rights to Chinese weight-loss drugs, as a fierce scramble for next-generation obesity t... |
| 11.02.2026 | Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH | SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have entere... |
| 14.10.2025 | HepQuant Announces Exciting New Data Utilizing HepQuant DuO® testing: Early Assessment of Resmetirom Treatment Benefit in Patients with Compensated MASH Cirrhosis | HepQuant, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, announces promising findings from a study utilizing the HepQuant DuO test to evaluate the impact of resmetirom treatment in patients wit... |
| 18.08.2025 | Novo Nordisk shares pop after Wegovy receives U.S. approval for liver disease | Novo Nordisk’s Wegovy was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis. It marks the first GLP-1 class therapy to be cleared for MASH. ... |
| 19.12.2024 | The Shifting Sands of Pharma and Energy: Opportunities Amidst Uncertainty | In the world of finance, change is the only constant. Two sectors currently in the spotlight are pharmaceuticals and energy. Both face unique challenges and opportunities. Investors must navigate these shifting sands carefully. Novo Nordisk... |
| 18.12.2024 | Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease. | Recent sales of a little-known stock, Madrigal Pharmaceuticals (NASDAQ: MDGL), could bode well for Novo Nordisk A/S (NYSE: NVO). The pharma industry giant has seen explosive sales growth for its GLP-1 agonist drug, semaglutide. Marketed th... |
| 07.05.2024 | Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates | On March 14, 2024, received U.S. FDA approval of Rezdiffra™ (resmetirom) for the treatment of patients with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis In April 2024, product shipped and first p... |
Show more